Skip to main content

Table 1 Demographic and clinical characteristics according to clinical diagnosis prior to [18F]flutemetamol PET

From: Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Pre-PET etiology AD
(n = 144)
FTD
(n = 28)
OD
(n = 19)
NN
(n = 20)
Age (years) 62 ± 6 (45–70) 62 ± 5 (52–69) 63 ± 6 (48–69) 60 ± 5 (49–69)
Gender, female 71 (49%) 13 (46%) 7 (37%) 4 (20%)
MMSE 23 ± 3 25 ± 3 24 ± 4 24 ± 4
CDR (0.5/1.0/2.0) 77/50/6 18/9/1 8/9/0 13/4/1
APOE genotype, e4 carrier 87 (67%) 7 (28%)a 10 (63%) 14 (78%)
Specified diagnosis 6 lv-PPA
138 AD
20 bvFTD
2 SD
6 PNFA
3 VaD
7 DLB
5 CBD
4 PSP
12 psychiatry
3 CTE
2 meningeoma
1 PTSS
1 OSAS
1 limbic encephalitis
  1. Data are presented as mean ± SD (range), n (%), or mean ± SD unless stated otherwise. Differences between groups were assessed using ANOVA with post-hoc Bonferroni tests (age and MMSE), χ2 tests (gender, APOE genotype), and Kruskal–Wallis with post-hoc Mann–Whitney U tests (CDR)
  2. aFTD < other diagnostic groups; P < 0.05
  3. PET positron emission tomography, MMSE Mini Mental State Examination, CDR clinical dementia rating. AD Alzheimer’s disease dementia, lv-PPA logopenic-variant primary progressive aphasia, FTD frontotemporal dementia, bvFTD behavioral variant FTD, SD semantic dementia, PNFA, primary nonfluent aphasia, OD other dementia diagnosis, NN non-neurodegenerative diagnosis, VaD vascular dementia DLB dementia with Lewy bodies, CBD corticobasal degeneration, PSP progressive supranuclear palsy, CTE chronic traumatic encephalopathy, PTSS posttraumatic stress syndrome, OSAS obstructive sleep apnea syndrome